The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Improved overall survival after the addition of rituximab to chemotherapy alone as first-line therapy for mantle cell lymphoma (MCL): Evidence from SEER-Medicare.
M. H. Dreyling
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
R. Griffiths
Consultant or Advisory Role - Genentech
M. Gleeson
Consultant or Advisory Role - Genentech
M. Danese
Consultant or Advisory Role - Genentech
J. Mikhael
No relevant relationships to disclose